Objective: To analyze the influence of stress and psychological resilience on the dietary behavior of middle school students so as to privide a basis for the development of policies and interventions aimed at improving middle school students dietary behavior. Methods: A total of 8 874 middle school students in Shanghai were surveyed using stratified cluster random sampling method from November 2019 to January 2020. The questionnaire included general information, dietary behavior, Perceived Stress Scale (PSS-10) and Connor-Davidson Resilience Scale (CD-RISC-10). Factor analysis was used to analyze the dietary behavior model. Logistic regression model was used to explore the correlation between stress, psychological resilience and dietary behavior in adolescents. Besides, a structural equation model was established to analyze the mediating effect of psychological resilience on stress and dietary behavior. Results: The total score of psychological resilience among middle school students was (27.99±9.83), and the total score of stress was (25.56±7.06). Factor analysis categorized dietary behavior into two types: the high energy dietary behavior and balanced dietary behavior. High energy dietary behavior exhibited statistically significant differences across genders and schooling stage ( χ 2=41.37, 204.03), while balanced dietary behavior showed statistically significant differences across schooling stage and socioeconomic status ( χ 2=130.23, 96.53) (all P <0.01). Logistic regression analysis showed that adolescents with moderate and high stress levels had an increased risks of high energy dietary behavior ( OR=1.25, 95%CI =1.12-1.39; OR=1.58, 95% CI = 1.39-1.79) and a reduced likelihood of reduced balanced dietary behavior ( OR=0.73, 95%CI =0.65-0.81; OR=0.53, 95%CI =0.47-0.60); adolescents with high levels of psychological resilience had a decreased risk of highenergy dietary behavior ( OR= 0.73 , 95%CI =0.65-0.83), and those with moderate and high resilience levels showed improved balanced dietary behavior ( OR= 1.45 , 95%CI =1.29-1.62; OR=2.50, 95%CI =2.21-2.84) (all P <0.01). The mediating effect of psychological resilience between stress and high energy dietary behavior or balanced dietary behavior accounted for 15.61% and 56.10% of the total effects, respectively. Conclusions Stress and psychological resilience are the influencing factors of dietary behavior in middle school students. Psychological resilience have a partial mediating effect between stress and high energy dietary behavior or balanced dietary behavior.

Objective To identify the key determinants that enhance the scientific innovation capabilities of leading dis-ciplines in tertiary hospitals and to construct a predictive model for scientific research outputs,providing a scientific basis for the integrated development of hospital disciplines.Methods This study focused on the orthopedics,endocrinology and metabolism,otolaryngology head and neck surgery,and nephrology departments at the Shanghai Sixth People's Hospital affiliated with Shang-hai Jiao Tong University School of Medicine.Research data from 2013 to 2022 were analyzed.Significant independent variables were identified through univariate analysis,and the LASSO regression model was applied to address multicollinearity issues,in-corporating the time lag effect of research output to construct a predictive model.Results The number of senior professional title holders and the number of enrolled master's and doctoral students emerged as key factors for scientific research outputs.Factors affecting the quality and quantity of article output included the number of senior professionals,the enrollment of master's,doctor-al,and postdoctoral students,and funding for provincial,ministerial,school,bureau,and hospital-level projects.Key factors in-fluencing project-based outputs included the number of senior professionals,doctoral supervisors,the number of enrolled master' s and doctoral students,and funding for school and bureau-level projects.The prediction model based on LASSO regression dem-onstrated a good fit for various research output indicators.Conclusion This study used LASSO regression to identify key factors in scientific research outputs for top disciplines.The predictive model built in the study offers a scientific basis for discipline de-velopment.It helps optimize resource allocation,strengthen interdisciplinary collaboration,and drive high-quality hospital devel-opment.

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Abstract Nutritional literacy is an important component of health literacy and closely related to adolescents dietary habits and health conditions. Improving nutrition literacy not only helps adolescents to make healthier dietary choices but also aids in disease prevention. The article systematically reviews the individual and environmental factors influencing adolescent nutrition literacy, with a focus on exploring innovative intervention strategies based on traditional school interventions, new media platforms and virtual reality technology, so as to provide a theoretical foundation and practical guidance for improving the nutrition literacy and overall health of Chinese adolescents.

Objective To construct a scientific and effective evaluation system for the medical science popularization a-bility of public hospitals,providing a reference for the evaluation and improvement of their medical science popularization abili-ties.Methods 27 experts from 6 public hospitals and 2 science popularization committees were invited to participate in two rounds of consultations.The Delphi method was used to screen evaluation indicators for medical science popularization ability,and the Analytic Hierarchy Process(AHP)was adopted to determine the weight of each indicator.Results The constructed e-valuation system for the medical science popularization ability of public hospitals includes 3 first-level indicators,7 second-level indicators,and 23 third-level indicators.The comprehensive weights of the third-level indicators range from 0.013 to 0.086.Conclusion The constructed evaluation system for the medical science popularization ability of public hospitals has a certain au-thority and scientific validity,which can provide a reference for promoting the evaluation of medical science popularization abili-ties in public hospitals.

Objective To construct a scientific and effective evaluation system for the medical science popularization a-bility of public hospitals,providing a reference for the evaluation and improvement of their medical science popularization abili-ties.Methods 27 experts from 6 public hospitals and 2 science popularization committees were invited to participate in two rounds of consultations.The Delphi method was used to screen evaluation indicators for medical science popularization ability,and the Analytic Hierarchy Process(AHP)was adopted to determine the weight of each indicator.Results The constructed e-valuation system for the medical science popularization ability of public hospitals includes 3 first-level indicators,7 second-level indicators,and 23 third-level indicators.The comprehensive weights of the third-level indicators range from 0.013 to 0.086.Conclusion The constructed evaluation system for the medical science popularization ability of public hospitals has a certain au-thority and scientific validity,which can provide a reference for promoting the evaluation of medical science popularization abili-ties in public hospitals.

Objective To identify the key determinants that enhance the scientific innovation capabilities of leading dis-ciplines in tertiary hospitals and to construct a predictive model for scientific research outputs,providing a scientific basis for the integrated development of hospital disciplines.Methods This study focused on the orthopedics,endocrinology and metabolism,otolaryngology head and neck surgery,and nephrology departments at the Shanghai Sixth People's Hospital affiliated with Shang-hai Jiao Tong University School of Medicine.Research data from 2013 to 2022 were analyzed.Significant independent variables were identified through univariate analysis,and the LASSO regression model was applied to address multicollinearity issues,in-corporating the time lag effect of research output to construct a predictive model.Results The number of senior professional title holders and the number of enrolled master's and doctoral students emerged as key factors for scientific research outputs.Factors affecting the quality and quantity of article output included the number of senior professionals,the enrollment of master's,doctor-al,and postdoctoral students,and funding for provincial,ministerial,school,bureau,and hospital-level projects.Key factors in-fluencing project-based outputs included the number of senior professionals,doctoral supervisors,the number of enrolled master' s and doctoral students,and funding for school and bureau-level projects.The prediction model based on LASSO regression dem-onstrated a good fit for various research output indicators.Conclusion This study used LASSO regression to identify key factors in scientific research outputs for top disciplines.The predictive model built in the study offers a scientific basis for discipline de-velopment.It helps optimize resource allocation,strengthen interdisciplinary collaboration,and drive high-quality hospital devel-opment.

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Background and purpose:For patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer,trastuzumab treatment can prolong the overall survival and significantly improve the prognosis of patients.However,the reference original research trastuzumab(Herceptin?)is more expensive.Biosimilars have comparable efficacy and safety profiles while increasing patient access to treatment.This clinical trial aimed to evaluate the efficacy,pharmacokinetics,safety and immunogenicity of the trastuzumab biosimilar AK-HER2 compared to trastuzumab(Herceptin?)in patients with HER2-positive metastatic breast cancer.Methods:This multi-center,randomised,double-blind phase Ⅲ clinical trial was conducted in 43 subcenters in China.This study complied with the research protocol,the ethical principles stated in the Declaration of Helsinki and the quality management standards for drug clinical trials.It was approved by the hospital's medical ethics committee.The clinical trial registration agency is the State Food and Drug Administration(clinical trial approval number:2015L04224;clinical trial registration number:CTR20170516).Written informed consent was obtained from subjects before enrollment.Enrolled patients were randomly assigned to the AK-HER2 group and the control group,respectively receiving AK-HER2 or trastuzumab(initial loading dose 8 mg/kg,maintenance dose 6 mg/kg,every 3 weeks as a treatment cycle,total treatment time is 16 cycles)in combination with docetaxel(75 mg/m2,treatment duration is at least 9 cycles).The primary endpoint of this clinical trial was the objective response rate(ORR9)between the AK-HER2 group and the control group in the 9th cycle.Secondary efficacy endpoints included ORR16,disease control rate(DCR),clinical benefit rate(CBR),progression-free survival(PFS)and 1-year survival rate.In this study,100 subjects(AK-HER2 group to control group=1:1)were randomly selected for blood sample collection after the 6th cycle of medication,The collection time points were 45 minutes after infusion(the end of administration),4,8,24,72,120,168,336,and 504 hours after the end of administration.After collection,blood samples were analyzed by PK parameter set(PKPS).Other evaluation parameters included safety and immunogenicity assessment.Results:A total of 550 patients with HER2-positive metastatic breast cancer were enrolled in this clinical trial between Sep.2017 and Mar.2021.In the AK-HER2 group(n=237),129 subjects in the experimental group achieved complete response(CR)or partial response(PR),and the ORR9 was 54.4%.There were 134 subjects in the control group(n=241)who achieved CR or PR,and the ORR9 was 55.6%.The ORR9 ratio between the AK-HER2 group and the control group was 97.9%[90%confidence interval(CI):85.4%-112.2%,P=0.784],which was not statistically significant.In all secondary efficacy endpoints,no statistically significant differences were observed between the two groups.We conducted a mean ratio analysis of pharmacokinetics(PK)parameters between the AK-HER2 group and the control group,and the results suggested that the pharmacokinetic characteristics of the two drugs are similar.The incidence of treatment emergent adverse event(TEAE)leading to drug reduction or suspension during trastuzumab treatment was 3.6%(10 cases)in the AK-HER2 group and 8.1%(22 cases)in the control group.There was statistically significant difference between the two groups(P=0.027).The incidence rate was significantly lower in the AK-HER2 group than in the control group,and there was no statistically significant difference among the other groups.The differences in the positive rates of anti-drug antibodies(ADA)and neutralizing antibodies(NAB)between groups were of no statistical significance(P=0.385 and P=0.752).Conclusion:In patients with HER2-positive metastatic breast cancer,AK-HER2 was comparable to the trastuzumab(Herceptin?)in terms of drug efficacy,pharmacokinetics,safety and immunogenicity.